Ardelyx(ARDX)2025-05-01 20:03Revenue Performance - Ardelyx reported total revenue of 44.4 million in Q1 2025, showing a significant year-over-year growth of approximately 57%[5] - XPHOZAH net product sales revenue was 3.8 million release of prior periods' estimated product returns[6] - Total revenues for the three months ended March 31, 2025, were 46,023 million in the same period of 2024[27] - Total product sales, net, reached 43,512 million year-over-year[27] - Licensing revenue surged to 17 million in the same quarter of 2024[27] Financial Position - The company ended Q1 2025 with 250.1 million at the end of 2024[8] Sales Forecast - Ardelyx expects full-year 2025 U.S. net product sales revenue for IBSRELA to be between 250.0 million[5] Expenses - Research and development expenses for Q1 2025 were 10.6 million in Q1 2024, reflecting increased engagement with the scientific community[12] - Selling, general and administrative expenses rose to 53.0 million in Q1 2024, primarily due to commercialization costs[12] - Research and development expenses increased to 10,579 million in the prior year[27] - Selling, general and administrative expenses rose significantly to 52,994 million in the previous year[27] - Total cost of goods sold was 7,128 million, reflecting a 72.5% increase year-over-year[27] Net Loss - The net loss for Q1 2025 was (0.17) per share, compared to a net loss of (0.11) per share, in Q1 2024[12] - The net loss for the quarter was 26,518 million in the same quarter of 2024[27] - Net loss per share of common stock was 0.11 in the prior year[27] - The company reported a loss from operations of 24,678 million in the same period last year[27] Leadership Changes - Ardelyx appointed Merdad Parsey, M.D. Ph.D., to its Board of Directors and Laura A. Williams, M.D., M.P.H., as the first Chief Patient Officer in April 2025[8] Milestone Payment - The company received a $5.0 million milestone payment from Fosun Pharma following the approval of tenapanor in China for hyperphosphatemia[8]